BCL2L1 and prostate cancer: Alternative splicing of the BCL-X gene generates two isoforms, where the shorter isoform BCL-XS is a tumor suppressor and downregulated in prostate cancer, while the longer isoform BCL-XL is an oncogene blocking apoptosis10.